Gyre Therapeutics has completed its acquisition of Cullgen in an all-stock deal valued at about $300 million, forming a fully integrated biopharmaceutical company based in the US and China. The combined company now offers a commercial product, ETUARY®, for lung fibrosis in China, and a robust pipeline including treatments for liver fibrosis and inflammatory diseases. Leadership changes include Dr. Ying Luo becoming CEO and President, with Ping Zhang remaining Chairman. The acquisition strengthens Gyre's position with innovative targeted protein degrader therapies and supports future global growth, with ongoing clinical trials and regulatory progress in China and plans for expansion outside China, including the US.
Asset Workflows Ltd, a UK-based asset data management firm, received a major strategic investment led by CoMade and two healthcare investors. This funding will accelerate its expansion in Australia and the Asia-Pacific region, enhance product develop...
Talk of a Tesla-SpaceX merger is intensifying as Elon Musk moves closer to taking SpaceX public. The two companies already share engineering talent and collaborate on energy, computing, and infrastructure challenges. The potential deal is largely dri...
TIFIN.AI has launched TIFIN Australia, a new joint venture aimed at bringing advanced AI technology to the Australian wealth management market. Led by experienced executives Marcus Price and Justin Schmitt, the platform will offer AI-native solutions...
Agora, Inc. announced its Q1 2026 financial results with revenues rising 13.5% to $37.7 million and net income increasing to $1.1 million, marking its sixth consecutive quarter of GAAP profitability. The company launched Agent Studio, a no-code platf...
Webco Industries reported a net income of $8.0 million for Q3 fiscal 2026, up from $5.0 million the previous year, driven by a 15.6% increase in net sales to $179.6 million. The company also saw improved gross profit margins and increased operating i...
